Quadrant Capital Group LLC Spring Works Therapeutics, Inc. Transaction History

Quadrant Capital Group LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$36.5 - $52.5 $839 - $1,207	23 New	23 $1,000
Q4 2022 Feb 10, 2023	SELL	$21.73 - $28.72 $369 - $488	-17 Reduced 24.64%	52 $1,000
Q3 2022 Nov 10, 2022	SELL	$24.1 - $39.66 $2,289 - $3,767	-95 Reduced 57.93%	69 $2,000
Q2 2022 Aug 09, 2022	BUY	$18.36 - $60.07 $3,011 - $9,851	164 New	164 $4,000

238

69.8M

144K

257K

Ticker SWTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,401,100
Market Cap $2.43B
Description
SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also deve...

Get notified when there are updates to the investment portfolio of Quadrant Capital Group LLC, based on Form 13F filings with the SEC.

Stay updated on Quadrant Capital Group LLC with notifications on news.